CD38 and neoplasm: Another correlative study of RRMM patients from the CoMMpass trial showed higher CD47 expression along with low CD38 expression correlated with worse overall survival and that dual inhibition of CD38 and CD47 had anti-tumor efficacy over single target inhibition (105).